Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

adenovirus expressing mutant HPV E6/E7

A cancer vaccine comprised of a genetically engineered, replication-deficient adenovirus encoding inactive, mutant forms of the human papillomavirus (HPV) transforming proteins E6 and E7, with potential immunostimulating and antineoplastic activities. Upon administration of adenovirus expressing mutant HPV E6/E7, the adenovirus infects and expresses the E6 and E7 proteins. The expressed E6 and E7 proteins stimulate the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing HPV E6 and E7, thereby inducing tumor cell lysis. Oncoproteins E6 and E7 play a key role in the development of cervical intraepithelial neoplasia (CIN) and cervical carcinoma.
Synonym:Ad-E6/E7
Ad-E6E7
adenoviral-expressing mutant HPV E6/E7
adenoviral-HPV E6E7 vaccine
adenoviral-HPV E6E7 vaccine
adenovirus vaccine expressing mutant HPV E6 and E7
Search NCI's Drug Dictionary